388 related articles for article (PubMed ID: 27913543)
1. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Meeks SL; Batsuli G
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
[TBL] [Abstract][Full Text] [Related]
2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Matino D; Makris M; Dwan K; D'Amico R; Iorio A
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Barthels M
Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
9. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
13. Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers.
Kaya Z; Orhan Ö; Turanlı S; Yenicesu İ; Koçak Ü; Gürsel T
Blood Coagul Fibrinolysis; 2017 Jul; 28(5):419-422. PubMed ID: 28079537
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
[TBL] [Abstract][Full Text] [Related]
15. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
Hay JW; Zhou ZY
J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
[TBL] [Abstract][Full Text] [Related]
16. Toward optimal therapy for inhibitors in hemophilia.
Kempton CL; Meeks SL
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):364-71. PubMed ID: 25696880
[TBL] [Abstract][Full Text] [Related]
17. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
[TBL] [Abstract][Full Text] [Related]
18. Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Barg AA; Levy-Mendelovich S; Avishai E; Dardik R; Misgav M; Kenet G; Livnat T
Pediatr Blood Cancer; 2018 Dec; 65(12):e27381. PubMed ID: 30230231
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
Young G; Escobar MA; Pipe SW; Cooper DL
Am J Hematol; 2017 Sep; 92(9):940-945. PubMed ID: 28589615
[TBL] [Abstract][Full Text] [Related]
20. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
Stephens JM; Joshi AV; Sumner M; Botteman MF
Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
